$CDT Cashflow Statement | Understand Stock

$CDT

$0.08 -$0.01 (14.89%) Close

$CDT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 2 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Formation costs paid by note payable – Sponsor
Interest earned on investments held in Trust Account
Gain on investment in equity securities
Gain on change in fair value of Cizzle option
Gain on change in fair value of Vela option
Loss on issuance of Vela option
Change in reserve for related party uncollectible loan
Loss on related party loan forgiveness
Compensation expense recognized for the issuance of shares and warrants in connection with the sale of a previously controlled subsidiary
Gain on debt extinguishment, net
Loss on debt extinguishment, net
Realized gain on short-term investments
Loss on disposal of crypto holdings
Gain on waiver of accrued interest
Unrealized foreign exchange gain / loss
Loss (gain) on change in fair value of convertible notes payable
Gain on change in fair value of warrants
Non-cash reduction of deferred income upon exercise of option liability
Gain on warrant remeasurement
Loss on issuance of warrants
Non-cash lease expense
Stock-based compensation expense
Issuance of common stock for licensing right
Non-cash interest expense
Depreciation expense
Amortization expense
Issuance of common stock for services
Issuance of common stock for services - related party
Amortization of debt discount
Gain (loss) on issuance of common stock for services
Changes in operating assets and liabilities:
Deferred offering costs
Prepaid expenses
Accrued expenses
Accrued income taxes payable
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Accrued litigation liability
Lease liability
Intangible assets

Net cash used in operating activities
Issuance of loan - related party
Purchases of property and equipment
Cash flows from investing activities:
Cash deposited into Trust Account
Purchase of digital assets
Proceeds from disposal of digital assets
Purchase of equipment and clinical assets
Purchases of short-term investments
Proceeds from the sale of short-term investments
Proceeds from issuance of option
Proceeds from loan repayment - related party
Net cash flows used in investing activities

Cash flows from financing activities:
Deferred offering costs
Proceeds from Merger and related PIPE Financing, net of transaction costs
Proceeds from the issuance of notes payable – related parties
Capital contribution - related party
Issuance of common stock
Proceeds from Issuance Initial Public Offering
Sale of private placement units
Payment of offering costs
Repayment of note payable - Sponsor
Proceeds from issuance of convertible notes payable, carried at fair value
Exercise of warrants
Issuance warrants
Proceeds from issuance of convertible promissory note payable, carried at cost
Proceeds from sale of equity securities
Repayment of notes payable - related parties
Repayment of convertible notes payable - related parties
Repayment of convertible notes payable
Purchases of treasury stock
Net cash flows provided by financing activities

Net change in cash and cash equivalents before effect of exchange rate changes
Effect of exchange rate changes on cash and cash equivalents
Net change in cash
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Deferred offering costs included in accrued offering costs
Prepaid expenses paid by note payable - Sponsor
Deferred offering costs paid by note payable - Sponsor
Deferred commission payable
Class A shares subject to redemption
Right of Use Asset obtained in exchange for Operating Lease Liabilities
Correction of immaterial error related to franchise tax expense
Issuance of Common Stock upon exercise of conversion option
Issuance of Common Stock in exchange for debt extension
Shares cancelled
Conversion of deferred commission payable to convertible promissory note
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option
Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC upon exercise of option
Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger
Deferred Underwriting Costs
Prepaid expense of directors and officers insurance paid out of PIPE financings proceeds in connection with the Merger
Accumulated deficit assumed to APIC as a result of the business combination
Initial value of warrant liabilities issued in connection with PIPE Financing
Non-Cash Assets Assumed in the Merger Financing
Non-Cash Liabilities Assumed in the Merger Financing
Fair value of shares received and receivable related to the sale of future revenue
Cash paid for interest
Cash paid for interest

Comments